Top

Clinical and Translational Oncology

Published in:

01-08-2017 | Research Article

Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis

Authors: H. Li, Z. Jin, X. Li, L. Wu, J. Jin

Published in: Clinical and Translational Oncology | Issue 8/2017

Abstract

Purpose

To assess the correlation between single-nucleotide polymorphisms (SNPs) and inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) in IBD patients.

Methods

A systematic search of PubMed, EmBase, and Cochrane databases was performed. Five genetic models (allelic, dominant, recessive, heterozygous and homozygous models) were used to analyze the associations, and trial sequential analysis was used to analyze the robustness of the results.

Results

We collected and analyzed the results of seven trials including a total of 2287 patients in our meta-analysis. A total of 8 SNPs were tested in IBD patients. For rs1800629 of TNF-α, the allelic model showed that polymorphism at this locus significantly increased the risk of IBD-associated CRC in IBD patients (OR 4.45, 95% CI 3.18–6.21, P < 0.001). The results also showed a significant association between rs1800629 and an IBD-associated CRC population (heterozygous model: OR 4.335, 95% CI 2.329–8.069, P < 0.001; homozygous model: OR 11.5, 95% CI 2.498–52.592, P = 0.002; dominant model: OR 4.986, 95% CI 2.754–9.026, P < 0.001; recessive model: OR 7.208, 95% CI 1.588–32.72, P = 0.01). Other studies have found that mutation of rs1143627 of IL1B (allelic model: OR 2.97; 95% CI 1.74–5.05, P < 0.001) and rs1050152 of OCTN1 (allelic model: OR 1.637, 95% CI 1.078–2.485, P = 0.021) increased the proportion of IBD-associated CRC in the population. Moreover, there were significant associations between IBD-associated CRC and ITLN rs2274910, gene desert rs1551398 and rs4871611, FCGR2A rs1801274, and S100-Z rs7712957 in the allelic model.

Conclusion

Associations between SNPs and the proportion of IBD-associated CRC in IBD patients were examined, and further investigation of additional SNPs and their association with the risk of morbidity is needed.

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54. doi:10.1053/j.gastro.2011.10.001.CrossRefPubMed

Martín-de-Carpi J, Rodríguez A, Ramos E, Jiménez S, Martínez-Gómez MJ, Medina E, SPIRIT-IBD Working Group of Sociedad Española de Gastroenterología, Hepatología y Nutricion Pediátrica. Increasing incidence of pediatric inflammatory bowel disease in Spain (1996–2009): the SPIRIT Registry. Inflamm Bowel Dis. 2013;19:73–80. doi:10.1002/ibd.22980.CrossRefPubMed

Martín-de-Carpi J, Rodríguez A, Ramos E, Jiménez S, Martínez-Gómez MJ, Medina E, Navas-López VM, SPIRIT-IBD Working Group of SEGHNP (Sociedad Española de Gastroenterología Hepatología Nutrición Pediátrica). The complete picture of changing pediatric inflammatory bowel disease incidence in Spain in 25 years (1985–2009): the experience registry. J Crohns Colitis. 2014;8:763–9. doi:10.1016/j.crohns.2014.01.005.CrossRefPubMed

Fernández A, Hernández V, Martínez-Ares D, Sanromán L, de Castro ML, Pineda JR, Carmona A, González-Portela C, Salgado C, Martínez-Cadilla J, Pereira S, García-Burriel JI, Vázquez S, Rodríguez-Prada I, EpiCom Group. Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study. Gastroenterol Hepatol. 2015;38:534–40. doi:10.1016/j.gastrohep.2015.03.001.CrossRefPubMed

Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006;12:3668–72. doi:10.3748/wjg.v12.i23.3668.CrossRefPubMedPubMedCentral

Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol. 2008;8:458–66. doi:10.1038/nri2340.CrossRefPubMed

Figueroa C, Peralta A, Herrera L, Castro P, Gutiérrez A, Valenzuela J, Aguillón JC, Quera R, Hermoso MA. NOD2/CARD15 and toll-like 4 receptor gene polymorphism in Chilean patients with inflammatory bowel disease. Eur Cytokine Netw. 2006;17:125–30.PubMed

Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012;143:382–9. doi:10.1053/j.gastro.2012.04.054.CrossRefPubMed

Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74. doi:10.1053/j.gastro.2009.12.035.CrossRefPubMed

10.

Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35. doi:10.1136/gut.48.4.526.CrossRefPubMedPubMedCentral

11.

Fan W, Maoqing W, Wangyang C, Fulan H, Dandan L, Jiaojiao R, Xinshu D, Binbin C, Yashuang Z. Relationship between the polymorphism of tumor necrosis factor-alpha-308 G > A and susceptibility to inflammatory bowel diseases and colorectal cancer: a meta-analysis. Eur J Hum Genet. 2011;19:432–7. doi:10.1038/ejhg.2010.159.CrossRefPubMedPubMedCentral

12.

Shivakumar BM, Rotti H, Vasudevan TG, Balakrishnan A, Chakrabarty S, Bhat G, Rao L, Pai CG, Satyamoorthy K. Copy number variations are progressively associated with the pathogenesis of colorectal cancer in ulcerative colitis. World J Gastroenterol. 2015;21:616–22. doi:10.3748/wjg.v21.i2.616.CrossRefPubMedPubMedCentral

13.

Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5. doi:10.1007/s10654-010-9491-z.CrossRefPubMed

14.

Chen J, Chatterjee N. Exploiting Hardy–Weinberg equilibrium for efficient screening of single SNP associations from case-control studies. Hum Hered. 2007;63:196–204. doi:10.1159/000099996.CrossRefPubMed

15.

Areeshi MY, Mandal RK, Panda AK, Bisht SC, Haque S. CD14 -159 C > T gene polymorphism with increased risk of tuberculosis: evidence from a meta-analysis. PLoS One. 2013;8:e64747. doi:10.1371/journal.pone.0064747.CrossRefPubMedPubMedCentral

16.

Liao LN, Chen CC, Wu FY, Lin CC, Hsiao JH, Chang CT, Kardia SL, Li TC, Tsai FJ. Identified single-nucleotide polymorphisms and haplotypes at 16q22.1 increase diabetic nephropathy risk in Han Chinese population. BMC Genet. 2014;15:113. doi:10.1186/s12863-014-0113-8.CrossRefPubMedPubMedCentral

17.

Garrity-Park MM, Loftus EV Jr, Bryant SC, Smyrk TC. A biomarker panel to detect synchronous neoplasm in non-neoplastic surveillance biopsies from patients with ulcerative colitis. Inflamm Bowel Dis. 2016;22:1568–74. doi:10.1097/MIB.0000000000000789.CrossRefPubMed

18.

Connelly TM, Berg AS, Harris LR 3rd, Brinton DL, Hegarty JP, Deiling SM, Stewart DB, Koltun WA. Ulcerative colitis neoplasia is not associated with common inflammatory bowel disease single-nucleotide polymorphisms. Surgery. 2014;156:253–62. doi:10.1016/j.surg.2014.03.017.CrossRefPubMed

19.

Martini M, Ferrara AM, Giachelia M, Panieri E, Siminovitch K, Galeotti T, Larocca LM, Pani G. Association of the OCTN1/1672T variant with increased risk for colorectal cancer in young individuals and ulcerative colitis patients. Inflamm Bowel Dis. 2012;18:439–48. doi:10.1002/ibd.21814.CrossRefPubMed

20.

Garrity-Park M, Loftus EV Jr, Sandborn WJ, Smyrk TC. Myeloperoxidase immunohistochemistry as a measure of disease activity in ulcerative colitis: association with ulcerative colitis-colorectal cancer, tumor necrosis factor polymorphism and RUNX3 methylation. Inflamm Bowel Dis. 2012;18:275–83. doi:10.1002/ibd.21681.CrossRefPubMed

21.

Garrity-Park MM, Loftus EV Jr, Bryant SC, Sandborn WJ, Smyrk TC. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2008;103:407–15. doi:10.1111/j.1572-0241.2007.01572.x.CrossRefPubMed

22.

Mahid SS, Colliver DW, Crawford NP, Martini BD, Doll MA, Hein DW, Cobbs GA, Petras RE, Galandiuk S. Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma. BMC Med Genet. 2007;8:28. doi:10.1186/1471-2350-8-28.CrossRefPubMedPubMedCentral

23.

Brentnall TA, Rubin CE, Crispin DA, Stevens A, Batchelor RH, Haggitt RC, Bronner MP, Evans JP, McCahill LE, Bilir N, Boland CR. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology. 1995;109:151–5. doi:10.1016/0016-5085(95)90280-5.CrossRefPubMed

24.

Guo XF, Wang J, Yu SJ, Song J, Ji MY, Cao Z, Zhang JX, Wang J, Dong WG. TNF-alpha-308 polymorphism and risk of digestive system cancers: a meta-analysis. World J Gastroenterol. 2013;19:9461–71. doi:10.3748/wjg.v19.i48.9461.CrossRefPubMedPubMedCentral

25.

Nagao M, Sato Y, Yamauchi A. Meta-analysis of interleukin polymorphisms and NSAID usage indicates correlation to the risk of developing cancer. Int J Genom Med. 2014;2:1000113.

26.

He B, Zhang Y, Pan Y, Xu Y, Gu L, Chen L, Wang S. Interleukin 1 beta (IL1B) promoter polymorphism and cancer risk: evidence from 47 published studies. Mutagenesis. 2011;26:637–42. doi:10.1093/mutage/ger025.CrossRefPubMed

27.

Angelini S, Pantaleo MA, Ravegnini G, Zenesini C, Cavrini G, Nannini M, Fumagalli E, Palassini E, Saponara M, Di Battista M, Casali PG, Hrelia P, Cantelli-Forti G, Biasco G. Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacol Res. 2013;68:1–6. doi:10.1016/j.phrs.2012.10.015.CrossRefPubMed

28.

Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K, Seya T. Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem. 2001;276:23456–63. doi:10.1074/jbc.M103162200.CrossRefPubMed

29.

Durães C, Machado JC, Portela F, Rodrigues S, Lago P, Cravo M, Ministro P, Marques M, Cremers I, Freitas J, Cotter J, Tavares L, Matos L, Medeiros I, Sousa R, Ramos J, Deus J, Caldeira P, Chagas C, Duarte MA, Gonçalves R, Loureiro R, Barros L, Bastos I, Cancela E, Moraes MC, Moreira MJ, Vieira AI, Magro F. Phenotype-genotype profiles in Crohn’s disease predicted by genetic markers in autophagy-related genes (GOIA study II). Inflamm Bowel Dis. 2013;19:230–9. doi:10.1002/ibd.23007.CrossRefPubMed

30.

Xia HZ, Du WD, Wu Q, Chen G, Zhou Y, Tang XF, Tang HY, Liu Y, Yang F, Ruan J, Xu S, Zuo XB, Zhang XJ. E-selectin rs5361 and FCGR2A rs1801274 variants were associated with increased risk of gastric cancer in a Chinese population. Mol Carcinog. 2012;51:597–607. doi:10.1002/mc.20828.CrossRefPubMed

31.

Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin ± cetuximab. BMC Cancer. 2014;14:340. doi:10.1186/1471-2407-14-340.CrossRefPubMedPubMedCentral

32.

Festen EA, Stokkers PC, van Diemen CC, van Bodegraven AA, Boezen HM, Crusius BJ, Hommes DW, van der Woude CJ, van der Woude JC, Balschun T, Verspaget HW, Schreiber S, de Jong DJ, Franke A, Dijkstra G, Wijmenga C, Weersma RK. Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk. Am J Gastroenterol. 2010;105:395–402. doi:10.1038/ajg.2009.576.CrossRefPubMed

33.

Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res. 2014;4:89–115.PubMedPubMedCentral

Title: Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis
Authors: H. Li
Z. Jin
X. Li
L. Wu
J. Jin
Publication date: 01-08-2017
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 8/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1634-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2017

The potential role of brachytherapy in the irradiation of patients with lung cancer: a systematic review

Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas

BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines

FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis

MicroRNAs as prognostic biomarker and relapse indicator in leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer